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 The purpose of the study was to determine how often and to what degree 
imprecise frequency descriptors are used in prescription drug print ads.  These 
descriptors along with the side effects they describe were compared to their 
corresponding prescription medicine websites and analyzed to determine whether or not 
the general public is being misinformed and/or misled in terms of side effect warnings by 
current drug advertising. Content analysis of Direct-to-Consumer (DTC) prescription 
drug advertisements found in five of the top seven magazines most likely to be consumed 
by readers over age 65 was the method of investigation for this study.  The time frame of 
the magazines studied, was, August 2002 to July 2003.  
    Using SPSS and descriptive statistics, results indicated that within DTC 
advertising, there is a great potential to mislead.  For example, all of the side effects listed 
in the advertisements were also listed on their corresponding drug websites.  Though, in 
some cases, the side effects with the highest incidence percentages on the websites were 
not listed at all in the advertised side effect warning.  Some side effects with incidence 
levels of over 30% on the websites were listed in the advertisements but were provided 
with imprecise frequency descriptors such as may include or most common.  The 
difference in website and magazine side effect descriptions present a question of 
credibility.  It appears from the discrepancy between the website side effect descriptions 
and magazine side effect warnings that the magazines are at best incomplete and 
probably misleading.    
 vi
  Possible suggestions for correcting the situation could include mandatory 
guidelines for side effect warnings including the number of side effects, inclusion of 








This study determines how often and to what degree imprecise frequency 
descriptors are used in direct-to-consumer prescription drug advertisements that appear 
in consumer magazines targeted at readers over age 65.  Much attention has been paid in 
recent years to the graying of America.  Jewler and Drewniany (2001) note, the 50-plus 
American population is 65 million strong and is growing larger everyday.  Every eight 
seconds, a baby boomer turns 50 (p. 37).   People over age 65 were chosen for this study 
because the magazines examined for content analysis are those most likely to be read by 
people in this age category according to Mediamark Research (2000).  Magazines were 
selected as the advertising medium to be measured because no media source is utilized 
more often for those in the 45 + age category than a book or magazine.  This includes 
such categories as watching television, going online, renting a movie, and listening to the 
radio according to a Jupiter Media Metrix survey of over 3,000 individuals in May 2001.            
In order to help the knowledge base of research on direct-to-consumer prescription drug 
advertisements, this study illustrates the prevalence, scale, and completeness of drug ads 
while attempting to better define risk statement completeness as applied to side effect 
warnings.  Cultivation Theory and Media Framing Theory will also be examined in 
relation to direct-to-consumer ads.   
Since direct-to-consumer advertising is such a recent trend, there is limited 
research on prescription drug ads and their impact.  This being the case, an exploratory 
study of what prescription drug ads are saying is called for.  The objective of this 
research is to determine whether or not the FDAs mandate of fair balance in regard to 
side effect warnings is being achieved in print drug advertisements.   
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Departing from the previous practice of promoting medications to doctors and 
pharmacists, pharmaceutical companies are now selling their products directly to patients 
through direct-to-consumer (DTC) prescription drug advertisements on television and in 
magazines (Lewis, 2003).  DTC prescription drug advertising is defined as any 
promotional effort by a pharmaceutical company to offer prescription drug information to 
the general public through consumer-oriented media (Pierpaoli, 1986).  Examples of this, 
which are given by the Food and Drug Administration, include, advertisements in 
published journals, magazines, other periodicals, and newspapers, and advertisements 
broadcast through media such as radio, television and telephone communication systems 
(Palumbo & Mullins, 2002, p. 428). 
The money spent on prescription drugs is the fastest growing expense in the 
health care industry, and many in the medical arena attribute this economic rise to the 
pharmaceutical industrys emphasis on DTC advertising (Melby, 2003).  Grant (1998) 
notes: It is hard to turn on the TV or open a magazine without seeing advertisements 
promoting the latest advances in baldness treatments or drugs for heart disease (p. 15).  
Consumer advocates claim the recent onslaught of prescription drug advertisements has 
resulted in patients demanding brand name prescriptions in place of less expensive, older, 
but still reliable medications (Melby, 2003). 
This concern was underscored in November 2003, when Congress passed a bill 
giving senior citizens the option to purchase a drug discount card that supporters say will 
save them up to 25%.  This voluntary drug benefit program starts in 2006 but includes 
premiums, deductibles, and shared costs.  According to supporters, senior citizens with 
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the highest drug bills will save the most money and those with minimal costs could 
possibly end up paying more than before (Stone, 2003). 
The content of DTC prescription drug advertisements is controlled by Food and 
Drug Administration (FDA) regulations which analyze prescription drug advertisements 
from a content perspective to be sure they are not, deceptive, misleading, or do not in 
other ways violate any applicable rules and regulations (Davis, 2000, p. 351).  
Furthermore, the FDA examines DTC prescription drug advertisements in terms of the 
principle of fair balance.   
The principle of fair balance requires that a DTC prescription drug print 
advertisement present a balance of risk and benefit information within the context of the 
advertisement.  However, the advertisers are not required to print all side-effects or risks, 
nor are they required to print the degree or severity of the possible side effects (Davis, 
2000).  Director of the Division of Drug Marketing, Advertising, & Communication, 
Thomas Abrams notes: the duty of the FDA is only to regulate the content of the 
promotion to ensure it is truthful and balanced (Edwards, 2003, p. 63).      
It was concluded in Davis (2000) research that: (1) Two equivalent drugs (with 
equivalent benefits and risks) may be perceived differentially by consumers because of 
differences in the number of side effects presented in their risk statements, and (2) 
Drugs appear to be safer than they actually are because of the number and types of side 
effects included in their risk statement (p. 366).  Therefore, the FDA concept of fair 
balance, which allows for incomplete information, may result in drugs appearing safer 
than they are.  Furthermore, consumers are more likely to make poor medical decisions 
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when they have incomplete or imperfect knowledge of the possible risks and benefits 
associated with alternate prescription drugs (Viscusi, Magat, & Huber, 1986).       
DTC prescription drug advertisements usually take one of three approaches to 
communicate drug related side effects.  The most precise approach in disclosing risk 
information provides percentages of drug related side effects and compares those levels 
to those observed in individuals in a placebo group, a slightly less precise approach to 
providing risk information, uses percentages of side effects without a placebo group. The 
third approach is the use of imprecise frequency descriptors (Davis, 1999).  Imprecise 
frequency descriptors consist of phrases such as, some people may experience, may 
cause, low incidence/occurrence and are not clearly defined anywhere else in the 
advertisements.      
The 40 million people over age sixty-five in the United States consume 40% of 
the prescription drugs sold (Price, 2003).  In a survey by Age Wave IMPACT, an 
integrated marketing firm that specializes in targeting older adults, it was concluded that, 
of more than 90% of people over 50 years old who said they saw or heard ads for 
prescription drugs, 35% went on to speak to their primary care physician about it (Hollon, 
1999).  Grant (1998) notes: Elderly patients who are most in danger of becoming over-
medicated were first to be targeted by prescription drug ads (p. 17).   
Davis (2000) states, further research is needed to help better define risk 
statement completeness (p. 367).  Davis (2000) also posed the following questions to be 
addressed in future research:   
1) Should completeness be defined in terms of the number of side effects 
reported? In terms of a minimum incidence level? In terms of the most common 
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side effects? And how is most common defined? 2) Does completeness require 
numeric indicators in the risk statement? For example, is the statement, the major 
side effects are headache and nausea equivalent in terms of completeness with 
the statement, the major side effects are headache (66%) and nausea (45%)? (pp. 
367-368).   
These questions remain unanswered.  The purpose of this study is to answer these 
questions and address prior researchers suggestions for further research.   
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LITERATURE REVIEW   
 Direct-to-Consumer prescription drug advertising was virtually unheard of 
until the early 1980s.  However, recently it has radically changed the way prescription 
drugs are marketed (Holtz, 1998).  As mentioned, DTC prescription drug ads are any 
promotional effort by a pharmaceutical company to offer prescription drug information to 
the general public through consumer-oriented media (Pierpaoli, 1986).   
Currently, pharmaceutical companies face no federal laws that restrict how they 
promote their products directly to consumers, and there is no limit on the amount of 
money used to finance those advertisements (see Appendix C).  In 2002, drug companies 
spent over $2.5 billion on DTC ads (Edwards, 2002).   It was recently reported that in 
2000, Merck spent the same amount ($161 million) on DTC advertising for Vioxx, as Dell 
Computers spent on its entire advertising campaign (Sullivan, 2002). 
Since DTC prescription drug advertising has only been prevalent for the past two 
decades, research on its effects on the public is limited.  Media spending in support of 
DTC drug advertising has increased considerably over the past several years, making 
DTC prescription drug advertising one of the fastest growing categories of consumer 
advertising (Davis, 1999).   
According to a 1998 Prevention magazine survey of consumer reactions to DTC 
advertising, one-third of the 163 million Americans who have seen or heard a DTC 
television, print or radio drug ad have spoken to their doctors about the medicine.  Of 
those, 15 million asked their doctor for the drug, and 80% left the office with a 
prescription in hand (Weissman, 1998).  
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Regulation of DTC Advertising 
Until the early 20th Century, individual states were responsible for regulating 
domestically produced foods and drugs (Swann, 2003).  During this time, newspapers, 
billboards, and store shelves were overflowing with patent medicines, all claiming to 
have amazing healing powers.  These medicines refer to unregulated products that were 
marketed to make money for their patent holders (Moyers, 2002). 
Many of the diseases these medicines claimed to cure, such as diabetes and 
cancer, are still incurable today.  Americans purchased these drugs because access to 
medical doctors was very limited and they had little money to spend on expensive 
prescription medicines. Several patent medicines contained high percentages of alcohol 
and narcotics, such as morphine, cocaine, and opium.  Others had ingredients now known 
to be very dangerous to the human body, like mercury, formaldehyde, and salicylic acid 
(Moyers, 2002).  Although these products made consumers feel better for a limited time, 
they didnt measure up to their claims of curing diseases ranging from the common cold 
to tuberculosis. 
By the end of the 19th Century, muckraking journalists began writing about these 
fraudulent drugs and their distributors.  Journalists like Samuel Hopkins Adams and 
Upton Sinclair exposed in gruesome detail the hazards of the marketplace, which later 
pushed Dr. Harvey Washington Wiley, a chemist in the Department of Agriculture, to 
encourage congressional action.  On June 30, 1906, after nearly 100 regulatory bills had 
been introduced to Congress, president Roosevelt signed the Food and Drugs Act also 
known as the Wiley Act.   The main premise of the law rested on the regulation of 
product labeling.  The food and drug labels could no longer be false or misleading, and 
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the presence and amount of dangerous ingredients such as alcohol, heroin, and cocaine 
had to be listed on the product (Swann, 2003). 
   In 1927, the Bureau of Chemistry became the Food, Drug, and Insecticide 
Administration.  Three years later, the name was shortened to its present version, the 
Food and Drug Administration (FDA).  In 1962, authority over prescription drug 
advertising was transferred from the Federal Trade Commission (FTC) to the FDA.  By 
1971, The FDA was granted explicit and primary authority over prescription drug 
advertising (Calfee, 2002). 
The FDA first dealt with direct-to-consumer promotion in the mid 1970s, issuing 
a regulation that authorized advertising prescription drugs to consumers as long as the 
pharmaceutical company made no representations about the safety or effectiveness of the 
product.  In 1983, the FDA requested a voluntary moratorium on DTC ads, due to the 
lack of formal policy concerning DTC advertisements, so that it could consider the issue 
in detail (Noah, 1997). 
In the two years following the moratorium on DTC ads, the FDA published two 
studies concerning the effects of prescription drug promotion aimed at the general public. 
One study, commissioned by the agency, showed that consumers retained more 
information about the advantages of products than about the risks.  This study also 
differentiated between print and broadcast, finding that print advertising was a better 
format for conveying lasting risk information (Morris & Millstein, 1984). The other study 
was conducted by the FDA itself in 1985, and it concluded that consumers wanted more 
information about prescription drugs specifically, and healthcare generally and would 
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view DTC advertising in a favorable light (Morris, Brinberg, Klimberg, Rivers, & 
Millstein, 1986). 
In 1985, the FDA lifted the freeze on DTC ads, concluding that, for the time being 
current regulations governing prescription drug advertising provide sufficient safeguards 
to protect consumers.  The FDA then persuaded the pharmaceutical industry to submit on 
a voluntary basis all proposed consumer promotions for informal pre-clearance (Noah, 
1997). 
The provisions the FDA first placed on advertising were one paragraph long, and 
required only that the advertisement include the drugs generic name and formula, and a 
brief summary describing the effectiveness of the drug and its risks (Palumbo & Mullins, 
2002).  The FDA then developed regulations that impart two major requirements on 
prescription drug advertisements.  First, print ads were required to give a brief 
summary of the drugs side effects, warnings, and precautions, as well as the indication 
for use.  In recent times, the brief summary has come to mean attaching much of the 
package insert with the advertisement (Noah, 1997).  Second, for DTC ads, the FDA has 
interpreted the fair balance doctrine to mean that balancing information should be in 
the primary text of the ad, in language understood by consumers, so they can evaluate 
drug benefit claims and form accurate opinions about the drugs (Kalb, Dunlop, McEnroe, 
& Stein, 2003).     
The FDA focuses on the specific information contained in the body of the 
advertisement and accepts multiple forms of risk presentation, ranging from specific 
quantitative data to the use of imprecise frequency descriptors.  As long as the 
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information presented provides equal emphasis on benefits and risk, and there is no 
significant risk of information, fair balance is assumed to exist (Davis, 1999).   
The FDA permits three types of DTC prescription drug advertisements: 1) 
product claim advertisements, which include both the product name and specific 
therapeutic claims, 2) reminder ads, which provide the name of a product without stating 
its use, and 3) help seeking ads, which inform consumers of new but unspecified 
treatment options for diseases or conditions (Gardner, Mintzes, & Ostry 2003). 
In 1985, Masson and Rubin of the Federal Trade Commission (FTC) summarized 
what they considered the benefits of direct ads in the New England Journal of Medicine 
(Grant, 1998).  They pointed out three main types of information communicated through 
DTC prescription drug advertising that help patients choose appropriate medications.  1) 
Direct ads educate consumers on the reality of diseases.  2) When a patient is informed of 
symptoms of such diseases, they are more likely to consult a doctor.  3) Ads can inform 
patients of side effects that may have been overlooked by a doctor (Grant, 1998).             
After ten years of regulating DTC advertising under the same system used for 
promotions directed at healthcare professionals, the FDA officially announced an interest 
in revisiting the issue.  In 1995, the agency published a notice announcing a public 
meeting and invited comments.  It was then that the FDA formally communicated its 
intent to reconsider direct-to-consumer advertising of prescription drugs (Noah, 1997).   
In 1997, the FDA issued a preliminary Guidance for Industry that reinterpreted 
FDA regulations without actually changing any regulations.  In restating traditional 
requirements, the Guidance stated that in addition to being non-deceptive, prescription 
drug ads must also: 1) include a major statement conveying all of the products most 
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important risk information in a consumer-friendly language, and 2) communicate all 
information relevant to the products indication, including limitations to use in consumer-
friendly language (Palumbo & Mullins, 2002). 
  The Guidance does provide recommendations for fulfilling the adequate provision 
requirement: 1) Disclosure in the advertisement of an operating toll-free number, 
through which the consumer should be given the option of having the labeling mailed to 
them in a timely manner or having it read to them over the phone.  2) Reference in the ad 
to an alternative mechanism, such as reference to a print advertisement, to provide 
package labeling to consumers with restricted access to the Internet or those who are 
uncomfortable actively requesting additional information.  3) Disclosure in the 
advertisement of an Internet web page address that provides access to the package 
labeling.  4) Disclosure in the ad that pharmacists, or healthcare provider, may provide 
additional information (FDA, 1999). 
In 1999, the FDA created a consumer survey on DTC advertisements.  After 
reviewing the preliminary survey results, a final Guidance on DTC advertising was 
released.  The requirements remained virtually unchanged from 1997.  The FDA also 
stated that it had not found any compelling evidence that DTC advertising had tended to 
cause any of the harms of which it had been accused (Calfee, 2002). 
The FDA does not have unlimited power to regulate prescription drug advertising.  For 
example, the agency can neither entirely prohibit nor routinely demand pre-clearance of 
proposed ad campaigns without some exceptional circumstances.  Also, in order to 
disseminate drug-advertising regulations, the FDA must use formal rulemaking 
procedures that provide interested parties with a right to demand a hearing.  In the past, 
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the agency has experienced various problems in using these types of procedures (Noah, 
1997).      
DTC Advertising Around the World 
 The United States and New Zealand are the only two countries in the world that 
allow prescription drug advertising.  In Europe, the European Union (EU) has required 
member states to prohibit direct-to-consumer advertising of prescription drugs.  The EU 
legislation bans all forms of prescription drug advertising aimed at the general public and 
also prohibits the distribution of free samples of prescription drugs to anyone other than 
people authorized to write prescriptions.  Prescription drug promotion may be aimed at 
doctors and pharmacists but is still subject to monitoring (Palumbo & Mullins, 2002). 
 The EU has however, recently began a limited experiment in which manufacturers 
would be allowed to provide consumers with information on treatments for three 
therapeutic categories through pamphlets and other materials, but only in response to 
consumer requests and in websites.  Those categories for which drug ads are being 
allowed are diabetes, AIDS, and asthma (Calfee, 2002). 
 Like Europe, Canada prohibits DTC promotion of prescription drugs.  The 
practice has been banned in Canada since 1949.  Recently, the Canadian Food and Drug 
Regulations have allowed ads that are aimed only at professionals and contain only the 
name, price, and quantity of the drug.  A self-regulation group know as the Therapeutic 
Products Programme (TPP) was given the power to monitor all prescription drug ads in 
Canada, but the Pharmaceutical Advisory Board (PAB) maintains a code of acceptable 
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electronic broadcast advertising standards, which apply only to ads to healthcare 
professionals (Palumbo & Mullins, 2002). 
 Although the EU prohibits DTC prescription ads, the widespread use of the 
Internet and digital television, and patient demand for product information leads many to 
believe that DTC advertising is inevitable in Europe.  Supporters of DTC advertising in 
Canada have also argued that Canadas strong regulations do little when Americas close 
border permits Canadians to view American advertisements through television, 
magazine, and even radio broadcasts (Palumbo & Mullins, 2002).   
 There is also a growing concern by those against DTC ads in Canada and Europe 
that treating prescription drugs as a commodity would eventually drive up the price of 
government-funded healthcare systems.  Both the Canadian government and the EU want 
to make sure that objective information is given to patients rather than information that is 
based strictly on profit as a motive (Sullivan, 2002). 
Like Europe and Canada, public healthcare is provided by the government in New 
Zealand, the only country other than the United States that allows DTC advertising of 
prescription drugs.  The Research Medicines Industry (RMI) Association of New 
Zealand, a non-profit professional trade association, has analyzed both sides of the debate 
and has come to the conclusion that DTC ads can serve a public benefit.  The RMI does 
believe however, that DTC ads may put pressure on the governments pharmaceutical 
budget and on doctors to prescribe drugs if requested by a patient.  The RMI has also 
concluded that these ads are driven by commercial considerations and are insufficient for 
consumers to make well-informed decisions.  Like the United States, New Zealand has 
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regulations regarding DTC ads.  For instance, the Fair Trading Act of 1986 makes unfair 
and misleading advertising an offense.  But also, much like the United States, it has been 
very unclear in the past as to which ads are unfair and misleading. (Collins, 2001) 
Research Concerning the Miscomprehension of DTC Advertising 
Because DTC prescription drug promotions are becoming increasingly more 
prevalent, the potential for misinformation and consumer misunderstanding is a major 
concern of the medical community (Krieger, 1983).  A 1992 study of physicians found 
that 88% of patients asked for a drug by brand name, up from 45% in 1989 (Liebman, 
1993).  Research by the FDA pointed out that about 25% of those who were exposed to 
DTC prescription drug ads asked their physicians about the medical conditions they saw 
in the ad (FDA, 1999). 
This concern may be well founded according to two studies.  In 2002, Balazs, 
Yermolivich, and Zinkham researched attitudes and information-seeking behavior related 
to DTC prescription drug advertising among the elderly.  The study concluded that DTC 
ads encouraged older consumers to seek more prescription drug information from friends 
and doctors.  More than 50% of the respondents asked doctors or pharmacists about a 
drug seen in DTC ads and 30% requested a specific medication by name.  About 20% 
asked about the medical condition they saw in DTC ads.  While this is good news for 
drug companies, the impact on consumers is less clear.        
A second study by Morris, Brinberg, Klimberg, Rivera, and Millstein (1986) 
examined the degree to which television and magazine ads for two fictitious drugs were 
miscomprehended.  The study found that over two-thirds of the respondents believed that 
a fabricated arthritis drug was better than aspirin when the scientific data for the class of 
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drugs allowed no such assumption.  They concluded that, the use of the term 
miscomprehension rather than the traditional term misleading implies that the receiver 
rather than the source or the message is the cause for the failure to correctly recall or 
identify certain information (p. 111). 
 Incomplete Risk Statements 
One problem that has been identified is with what researchers call incomplete risk 
statements.  The incomplete risk statement, has the operational definition: a subset of 
all potential side effects are always presented, and in all cases, not all side effects at or 
above the 3% criterion are presented. (Davis, 2000, p. 351)  For example, like any 
prescription drug, Fosamax may cause side effects.  The most common side effects are: 
stomach and muscle, bone or joint pain (p. 351).   
Davis (2000) study examined the relationship between risk statement 
completeness and the perceptions of DTC advertised prescription drugs, concluding, 
consumers rate the safety and appeal of drugs described with an incomplete risk 
statement significantly more positive than comparable drugs described with a more 
complete risk statement (p. 349).  In seven of the eight cases studied, consumers were 
considerably more likely to recommend or purchase a drug when the description was 
accompanied by an incomplete risk statement instead of a complete risk statement.  
The 1998 Prevention magazine survey also concluded that only 21% of 
consumers who see DTC ads think they are very clear.  Many people who saw an ad for a 
brand-name drug later said they did not know what the drug was for, even if they 
themselves had the symptoms described in the ad (Weissman, 1998).  
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Davis 1999 study concluded that, Consumers cannot accurately estimate side 
effect incidence when that effect is described by an imprecise frequency descriptor; in all 
but one case, consumers average estimate of a side effects incidence greatly exceeds the 
actual level of that effect and in the remaining case greatly underestimates actual level of 
incidence (p. 142). 
Cultivation Theory 
Cultivation Theory argues that media cultivates or creates a worldview that, 
although possibly inaccurate, becomes the reality because people believe it to be so 
(Baran & Davis, 2003).  This being the case, a careful study of exactly what ads say will 
be helpful in determining why the elderly feel encouraged to request these medicines.  
While no previous study has linked Cultivation Theory to DTC prescription drug 
advertising, it is still a viable theory today, recent studies have examined Cultivation and 
its connection between levels of acculturation, viewing of daytime television talk shows, 
and beliefs about social reality (Woo & Dominick, 2003).  Another set of research by 
Gross and Aday (2003), tested Cultivation Theory by comparing the effects of watching 
local news broadcasts with direct experience measures of crime and the fear of 
victimization. statistics indicate it is occurring.  Research by the Kaiser Family 
Foundation (2001) found that DTC ads prompt many people, especially the elderly and 
those in poor health, to talk to their doctors about a medicine they have seen advertised.   
Media Framing Theory 
The theory of media framing can be addressed when studying the effects of 
incomplete frequency descriptors, such as in rare cases, low incidence, and most 
common.  In the 1920s, Walter Lippman proposed that the media would control public 
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opinion by focusing attention on selected issues while ignoring others (Baran & Davis, 
2003).  Although Lippman was concentrating on newspaper readership, this theory could 
be applied to advertisements as well.   
For instance, in a study by Bell, Kravitz, and Wilkes (1999), it was concluded that many 
people mistakenly believe that DTC advertisements go through preliminary review by 
government regulators and that only completely safe and extremely effective drugs 
can be advertised.  The subjects who held these incorrect beliefs tended to be more aware 
of DTC ads and were more willing to act on them.  With flowery language and happy 
people frolicking in fields of wild flowers, DTC prescription drug ads are framing drugs 
and possibly making the risks associated with them seem less threatening.  
The warnings presented in DTC drug ads are only partially absorbed by 
consumers, leaving them an overall perception that the advertised ailment is safely 
treatable, and not with the feeling that there is the possibility that the treatment may be 
unsafe or inappropriate in many cases (Melby, 2003).  The American Medical 
Association argues that the current advertising offers only snippets of information, 
instead of more substantial data that a patient might need to make a truly informed 
decision (Marks, 2001).             
Surveys of patients by the FDA emphasize that the quality of information 
provided in DTC advertising is questionable.  These surveys point out the inadequacies of 
the information presented by drug marketers, and patients misconceptions about rules 
governing the quality and content of DTC advertising (Hollen, 2004).  In one FDA 
consumer survey, 58% of the respondents said that the advertisements make the drugs 
seem better than they are. (Henney, 2000, p. 2242) 
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Although there is very little research regarding media framing, it is still used in 
various realms of mass communication studies today.  For example, a recent study by 
Zavestoski, Agnello, Mignano, & Darroch (2004), explores media framing of toxic crises 
and apathy of theses events by local citizens.  Another study by Fuyuan (2004), examined 
the effects of media framing on voter understanding of political campaign advertisements 
in an attempt to understand the relationship between media frames and audience 
responses.  
  This study will forward the understanding of cultivation and media framing 
theories by applying them to magazine advertisements.  Little research on the effects of 
direct-to-consumer prescription drug promotions and a great and growing concern for the 
effects of this type of advertising make this an important issue. 
This leads to the following research questions. 
RQ1:  How complete is print drug advertising in regard to side effects? 
RQ2:  Do actual percentages of side effects listed on websites correspond to side effect  
frequency descriptors used in print ads?   
RQ3:  Are certain side effects more common? 




Content analysis was chosen as the method of investigation for this study.  In 
content analysis, certain aspects of the occurrence under study are coded and analyzed to 
disclose information.   
The goal of this content analysis was to determine how complete direct-to-
consumer prescription drug advertising actually is.  Because of this consumer focus, the 
sampling frame was consumer magazines rather than medical journals.  In order to locate 
magazines likely to feature prescription drugs, the sampling frame was drawn from those 
likely to be read by the elderly, who make up a large portion of the prescription drug 
market.   
Unit of Analysis 
In this study, the units of analysis were prescription drug advertisements found 
five of the top seven consumer magazines most likely to be read by the elderly.  In order 
for an advertisement to be coded, it had to appear in one of the five magazines chosen 
between the months of August 2002 and July 2003.  The top seven consumer magazines 
were chosen for two reasons: 1) to ensure manageability of the sample size; and 2) the 
elderly are the largest target audience of prescription drug advertisers.  According to 
Mediamark Research Inc. (2000), the consumer magazines with the highest readership of 
people over age 65 are: Modern Maturity1 (also known as AARP the Magazine), Catholic 
Digest, Yankee, Saturday Evening Post, and Prevention.  VFW Magazine and American 
Legion Magazine were listed in the Mediamark (2000) study before Catholic Digest, 
                                                
1 Modern Maturity changed its name to AARP the Magazine in April 2003, and will hereafter be 
referred to as AARP the Magazine. 
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Yankee, Saturday Evening Post, and Prevention but were not evaluated because they are 
read by a primarily male audience and are not consumer magazines. 
Coding Sheet A 
Prescription drug advertisements were analyzed using a coding sheet (see 
Appendix A).  The coding sheet includes, magazine name, date, and page number on 
which ad appears.  If an ad was more than one page long, the number of pages was 
recorded and the size of the pages coded.  Font size of the ad was also coded.  The 
number of side effects listed was noted as well.  Some ads do not contain side effect 
warnings; the frequency of the occurrence of these types of ads was also recorded.  The 
ad size and number of side effects listed was correlated using Pearsons product-moment 
correlation coefficient.   
Imprecise frequency descriptors were also coded.  Examples of these imprecise 
frequency descriptors are:  in rare cases, may include, less commonly, most 
frequently,  may cause, low incidence/occurrence, may occur, some people may 
experience, and usually mild. 
The product, or prescription name, and product category were recorded on the 
coding sheet.  The product categories consist of: 1) pain relief, 2) depression/mood, 3) 
health aid, 4) asthma/allergy, and 5) other.  For example, Lipitor is a prescription drug for 
high cholesterol and would fit in the health aid category.  Glucovance, a prescription 
drug used to aid in controlling Type II Diabetes would also fit in the health aid 
category.   There is a blank space next to other for the drugs that do not fit the first four 
categories.       
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The occurrence of a call to action was also noted.  The categories of a call to 
action by the ad include, whether or not the ad urges the consumer to: 1) contact his/her 
physician, 2) contact a pharmacist, 3) visit website listed on ad, or 4) call toll free number 
listed on ad.   
The size of the warning and the size of the ad were coded using width by height in 
picas and converted into inches to determine the area of the warning.  The type size of the 
warning and the total area of the warning were coded using a pica ruler, which uses a 
base 10 unit of measure called picas.  Pica measurement is common in visual layout.  The 
height type of the individual letters and words of the warning were measured in points 
and compared to that of the title of the advertisement.   
The occurrence of foldout ads were recorded as well as the use of inside front 
cover, inside back cover, or back page covers.  These are noteworthy as publishers 
typically charge advertisers more for these choice locations.  They also usually require 
that cover space be full- page and in four colors (Jugenheimer, Barban, & Turk, 1992).  
Layout of the ad was also analyzed by whether it is single or multi-page, whether the 
warning is written in color or in black and white, and if the ad itself contains color or is 
completely black and white.   
The presence of a detailed description of the drug within the ad was recorded as 
well as the type size of the description.  The occurrence of a celebrity spokesperson or 
famous endorser of the drug was also recorded as well as the name of that celebrity.       
Coding Sheet B 
A second coding sheet (see Appendix B) was used to evaluate prescription drug 
websites.  The coding sheet contains the name of the product, as well as its website.  The 
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number of side effects listed on the site in addition to the occurrence of percentages of 
those effects was coded.  If the drug website warning does contain percentages, each side 
effect and its percentage were listed and compared to the drugs corresponding print ad.       
Two coders were used and trained with descriptors beforehand.  A 10% overlap 
was evaluated for intercoder reliability or intercoder agreement. 
 23
RESULTS 
One hundred sixty-five advertisements were analyzed in 50 magazines. These 50 
came from five different publications (AARP the Magazine, Catholic Digest, Yankee, 
Saturday Evening Post, and Prevention), which are among the top seven read by those 
age 65 and older (MediaMark, 2000). The time frame studied was August 2002 to July 
2003. AARP the Magazine yielded 24 drug advertisements, Catholic Digest contained 
eight, Yankee contained three, Saturday Evening Post contained 41, and Prevention 
contained 89.   
A second coder coded 10% of the ads. Individual observed agreement ranged 
from 82% to 100 % with an average of 98%. 
Every ad analyzed took up at least one full magazine page.  One ad (.6%) was five 
pages long, 11% (22) of the ads were four pages long, and 29.1% (48) were three pages 
long.  Fifty-one point five percent (85) were two pages long and only 5.5% (9) of the ads 
were one page long. The type size of the advertisements titles ranged from one (.6%) 
advertisement with a 10-point title to 1.8% (3) of the ads having 46-point titles.  Sixteen-
point font (20%) was the most common size used.  Over 51.5% of the ads analyzed had 
titles that were written in less than 20-point font size.  
Of the 165 ads coded, 93.9 % contained a side effect warning. While just over 6% 
of the ads contained no side effect warnings, 8.5% had one side effect listed, 8.5% had 
two side effects listed, 29.1% had three side effects listed and 29.7% had four side effects 
listed (see Table 1).  Warnings with fewer than four listed side effects made up over 52% 




Side Effect Occurrence in Advertisements 
    Number of side             Frequency Percent Cumulative percent 
      effects listed 
 
0         10         6.1   6.1 
1         14     8.5             14.5 
2         14                 8.5                           23.0  
3          48                 29.1             52.1 
4         49     29.7             81.8 
5          9     5.5                           87.3 
6          2                  1.2                           88.5  
7         10     6.1             94.5 
8          8       4.8                           99.4 
11          1                 .6             100  
 
One hundred thirty two (81%) ads contained imprecise frequency descriptors.  In 
those 132 ads, 13 different imprecise frequency descriptors were used.  Most common 
was used 38.6% (51) of the time to describe the severity of the side effects listed.  
Usually mild was listed as an imprecise frequency descriptor in 27.3% (36) of the 
advertisements.  The IFD used that were not listed on the coding sheet were commonly 
reported and more often which were listed 1% (2) and 3.5% (7) of the time 
respectively.  The only two IFDs that were listed on the coding sheet but were not used 
in the ads were, could cause and may increase. 
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Sixty side effects were identified in the ads (not including side effects listed on 
the websites).  The number of side effects listed in the ads ranged from 11 (.6%) to zero 
(6.1%).  Eight-point five percent  (14) of the ads contained one side effect, 8.5% (14) also 
listed two effects, 29.1% (48) listed three effects, and 5.5% (9) listed five side effects.  
One point two percent (2) of the ads contained six side effects, 6.1% (10) listed seven 
effects, and 4.8% (8) of the ads listed eight side effects in their warnings.  The most 
common number of side effects listed was four, which was listed 29.7% (49) of the time.  
Drug advertisements that listed three or less side effects made up 52.1 % of the total ads.      
Of the 60 different side effects used in the drug advertisements, diarrhea was 
listed 34.8% (54) of the time in the 165 ads analyzed.  Headache was a side effect for 
25.8% (40) of the ads, nausea/upset stomach was listed 21.3% (33) of the time, 
stomach/abdominal pain was listed 18.1% (28) of the time, and muscle pain/cramps 
/weakness was listed in 17.4% (27) of the 165 ads coded. 
In regard to the websites, all 33 prescription drugs advertised had websites, 
however, 7% (14) of the 165 ads did not provide the drugs web addresses.  Eighty-five 
side effects were listed on the websites.  Of the 85 side effects listed, headache was 
mentioned as a side effect for 21 of the 33 medicines.  The most common side effects in 
occurrence in the website drug descriptions were, headache, listed for 69.6% (23) of 
the drugs, nausea/upset stomach for 66.7% (22), fatigue/asthenia/lack of strength for 
54.5% (18), and stomach/abdominal pain, diarrhea, and dizziness were each listed 
as side effects for 51.5% (17) of the 33 drugs.  
Of the 33 prescription medicines that made up the 165 ads analyzed, fourteen of 
the 33 drugs were advertised at least five or more times each.  Zocor, a prescription 
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medicine for high cholesterol, was advertised in 8.5% or 14 different times in the 165 
total ads.  Vioxx, a drug used to treat pain associated with Osteoarthritis, was advertised 
7.9% of the time (13 ads), Nexium, a prescription for heartburn was advertised 7.3% of 
the time (12 ads), Plavix a prescription medicine that helps prevent heart attacks and 
strokes was advertised 6.7% of the time (11 ads), and Allegra, a prescription allergy 
medicine, Procrit, a drug for chemotherapy related anemia, and Singulair, an asthma 
drug were each advertised 6.1% of the time (10 ads).  There were eight drugs advertised 
only one time, making up 0.6 % each of the total drugs promoted.    
The medications were identified in five categories as described in the methods 
section. Of the 33 advertised medications, 30% (49) of the ads were for health aid, 
which contains such drugs as those listed for high cholesterol, hypertension, and type II 
diabetes.  Approximately 28% (46) medicines were in the others category. The others 
category included ads for drugs that did not fit in the health aid, allergy, 
depression, or pain relief.  Examples of the drugs placed in the other category are, 
Arimidex, an early breast cancer treatment and Aricept, a medicine for the treatment of 
early symptoms related to Alzheimers disease.  Procrit a drug for chemotherapy related 
anemia, and Plavix, a medicine for the prevention of blood clots were also placed in the 
other category.  Twenty-three percent (38) were for pain relief, 19% (31) were for 
Asthma/Allergy, and 0.6% (1) drug was for depression.  
Every single one of the 165 ads contained a call to action, including those ads for 
Vioxx and Procrit that did not contain side effect warnings. Content categories for the call 
to action were, (1) contact physician, (2) contact pharmacist, (3) link to website, and (4) 
toll free number.  All 165 (100%) ads analyzed advised readers to contact their physician 
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regarding the advertised drug, however, none of the ads advised readers to call a 
pharmacist. A toll free number was available in 93.3% (154) of the ads, and a link to the 
prescription website was provided in 91.5% (151) of the ads.  
The average area of the side effect warning was three inches. However, the sizes 
of the magazines need to be taken into account.  Saturday Evening Post (8 X 10 ¾) was 
the largest magazine, while Prevention and Catholic Digest (5¼ X 7½) were the smallest.  
AARP the Magazine (8 X 10½) and Yankee (6 X 9) fell between the others in terms of 
size.          
The type size of the warning ranged from 6 to 12 points.  Approximately 53.9% 
(89) of the warnings were in 8-point.  Twenty-two point four percent (37) were in 6-
point, 17% (28) were in 10-point.  There was 0.6% (1) ad with a 12-point side effect 
warning.  The other 6.1 % were the 10 advertisements that did not contain a side effect 
warning at all.   
None of the ads were fold-out, on inside back covers or outside back covers, but 
95% (157) of the 165 ads were multi-page. Only nine of the ads were on single pages and 
they were all for Vioxx. 
There were 6.1% (10) inside front cover ads. All these were in Prevention 
Magazine.  Although this position only made up 6.1% of the total advertisements, the 
inside front cover had more prescription medication ads than any other location. 
All of the ads were in color, although 49.7% (77) of the side effect warnings were in 
black and white. 
Vioxx was the only medicine advertised that did not contain a detailed description 
with every one of its ads.  The other 94% (156) of the ads contained detailed descriptions 
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of their respective drugs.  Although nine Vioxx ads did not contain a detailed description 
of the drug, four ads for the product did. 
Celebrity endorsers were shown in 13.5% (22) of the ads. The six celebrity 
endorsers were professional figure skater Dorothy Hamill for Vioxx, professional golfers 
Jack Nicklaus for Altace and Nancy Lopez for Synvisc, and NFL football coach Dan 
Reeves in an ad for Zocor. 
In regard to the highest recorded incidents of the side effects on the websites, 
application or injection site reaction led (47% listed incidence) followed by cold and 
flu symptoms (39.7%), upper respiratory infection (38.1%), hot flashes (35%), and 
nausea (31%).     
On the websites, percentages of side effect occurrence were listed for 90.9% (30) 
of the medicines.  The three websites (9.1%) that did not contain percentages were for 
Viagra, Synvisc, and Noritate.    
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DISCUSSION 
Magazines for senior citizens are replete with ads for prescription drugs although 
some were much more heavily inclined in this area than others.  For instance, Prevention 
had twenty-nine times more ads than Yankee for the same time period.  Although both of 
these magazines are published on a monthly basis, two of the magazines analyzed were 
not.  AARP the Magazine and Saturday Evening Post are published bi-monthly.  
Although this doesnt explain why some magazines contained more ads than others, it 
does indicate that had these magazines been published every month, there would most 
likely have been over two hundred ads in the five magazines analyzed in the one year 
time period studied.    
Most of the ads did contain side effect warnings, although it is surprising that not 
all did.  Six point one percent (10) of the ads contained no side effect warnings 
whatsoever. While this may not seem significant in the grand scheme, all but one of the 
10 ads were for Vioxx, the other was a single ad for Procrit.  It is also surprising that 
although Vioxx was analyzed nine times without a side effect warning, it did contain a 
side effect warning and detailed description for four of its advertisements.  
Although almost 20% (31) of the ads coded did not contain imprecise frequency 
descriptors, it must be considered that 10 of those 31 ads must be disregarded because 
they contained no side effect warning at all.  So, in actuality there were only 21 ads out of 
the 165, which listed side effects but used no imprecise frequency descriptors.   
RQ1 asked, How complete is print drug advertising in regard to side effects? 
Using the websites as a benchmark, it appears the ads fall very short of being complete. 
Of more concern is the possibility that the ads are actually misleading. For instance, 
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while Protopic lists a 47% incidence of application or injection site reaction among 
users on their website, its magazine advertising does not include application site 
reaction at all, much less as one of Protopics most common side effects.  Likewise, 
Xenical lists a 39.7% incidence of cold and flu like symptoms and 38.1% incidence of 
upper respiratory infection among its prescription users on its website, while the drugs 
advertisements dont list cold and flu like symptoms or upper respiratory infection at 
all as one of Xenicals side effects.  It seems unlikely that consumers faced with 
imprecise frequency descriptors such as some people may experience and most 
common would realize the incidence level was over 37%, or one in three people who try 
the medicine are likely to experience the side effects (See Table 2). 
Table 2                                                                   
 Side Effects Listed on Websites with Highest Percentages of Incidence                       
    Drug         Side effect      Incidence       IFD from              Does ad warning    
                                         Percentage    from ad            list web side effect                              
 
    Protopic     application site reaction      47%          most common   no 
    Xenical           cold/flu symptoms         39.7%  some people may experience     no 
    Xenical      upper respiratory infection   38.1%   some people may experience    no        
    Arimidex           hot flash          35%          most common            yes   
    Effexor XR        nausea          31%          may include              yes   
 
This ambiguity of the language used to describe high side effect incidence levels 
is only part of the problem. The warnings on the magazine ads themselves do not appear 
to be presented in a way that is conducive to senior citizen comprehension. While this 
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was described in the earlier justification and literature review, this study further supports 
this viewpoint. 
For instance, side effect warning point sizes ranged from only 12 points to 6 
points. Considering that most seniors are afflicted with presbyopia, a condition that 
causes near vision to fade starting in the early to mid 40s.  Presbyopia is the most 
common eye condition in the United States, and is estimated to affect over 90 million 
Americans between now and 2014 (Lee & Bailey, 2004).  Because of this age related eye 
condition, the type size used may be unreadable to many consumers of the magazines 
studied. 
Framing theory suggests that media messages are packaged so as to allow certain 
desirable interpretations and rule out others.  If this is true with prescriptive medications, 
consumers who read only magazines and do not call toll-free numbers or utilize websites 
are unlikely to see the full picture.  By pointing out the discrepancies between the 
advertised side effect warnings and the actual prescribing information listed on drug 
websites, this study indicates that DTC prescription drug advertisements are leaving out 
valuable information thereby framing exactly what they want consumers to know about 
their respective medicines.         
Because this study did not contain human subjects or consumer evaluations, it is 
more difficult to prove Cultivation Theory in relation to direct-to-consumer advertising.  
It would however be quite useful in future research involving surveys or experiments 
regarding magazine promotions of prescription drugs.  For example, subjects could be 
asked to read a years subscription to the five magazines chosen, and then asked to fill 
out a questionnaire regarding the ailments, drugs advertised, and side effects listed for 
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each advertisement.  This type of study would better explore the realm of Cultivation 
Theory in regard to advertisements.     
The difference in website and magazine side effect descriptions presents a 
question of credibility. The magazine ads side effect warnings are presented in an 
authoritative manner, which may lead many consumers to assume they are definitive. It 
appears from the discrepancy between website side effect descriptions and magazine side 
effect warnings that the magazines are at best, incomplete and probably misleading.  A 
future study examining prescription drug package inserts and comparing them with drug 
websites and magazine print ads would help better explain the differences this study 
illustrated between ads and websites. 
 RQ2 was Do actual percentages of side effects listed on websites correspond to 
side effect frequency descriptors used in print ads?  All of the side effects listed in the 
advertisement warnings were also listed on their corresponding drug websites.  Though, 
in some cases, the most common side effect listed on the website was not listed in the 
advertised side effect warning.  As mentioned previously, the drug Protopic lists 
application site reaction as having a 47% incidence rate on its website, however, in the 
drugs advertisement, it doesnt list application site reaction at all.  It does list 
stinging, burning, and itching, as its most common side effects which could be 
ascertained as application site reactions, but it still doesnt justify why application site 
reaction was not listed at all.   
 Unlike Protopic, the prescription drug Arimidex lists hot flash as a side effect 
that is most common in its advertisement, and also lists hot flash on its website as 
occurring 35% of the time.  Likewise, Effexor lists nausea with the imprecise frequency 
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descriptor may include in its ad, but lists nausea with a 31% chance of occurrence on 
its website.  It is highly unlikely that consumers read a phrase such as may include and 
even possibly most common, and estimate that an average of two out of five people 
who are prescribed these medicines also experience these side effects.        
 RQ3 was Are certain side effects more common? Certain side effects definitely 
were more common, however, there was a serendipitous finding. In the ads, diarrhea 
was the most common side effect, while on the website, headache was listed most 
often.  Although the advertisements and websites did not have the same side effect listed 
most often, they did have four of the same side effects in each of their top five side 
effects in occurrence.  Four of the top five side effects they shared were, headache, 
diarrhea, nausea/upset stomach, and stomach/abdominal pain (See Table 3).  
 It must also be taken into consideration that the drug ads listed 60 side effects, 
while the drug websites listed 85 different side effects.  This is the reason for the large 
difference in the percentages of occurrence listed for each side effect in the ads and on 
websites.  If a reader relied on the print ads alone, he or she would get no information 
about 25 other side effects.        
 RQ4 was Does ad size or ad length correlate to the number of side effects listed? 
A simple look at descriptive statistics suggests ad size does not positively correlate with 
number of side effects. The longest ad was five pages and the shortest was one page. The 
most side effects listed were 11 and the least were zero. If longer ads correlated to a 
greater number of side effects, we would expect to find the ads with five pages tending to 
have more side effects than those with one page. This was not the case.  It was discovered 
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however, that two pages was the most common length of a prescription advertisement, 
and that a magazine is twice as likely to have a four-page ad than a single page ad.  
Table 3 
Advertised Side Effects Compared with Drug Website Side Effects 
Ad Side Effect           % of Occurrence        Website Side Effect               % of Occurrence 
                                         ( X / 165)          (X / 33)   
 
diarrhea                34.8 %     headache                   69.7 %  
headache            25.8 %     nausea                   66.7 %  
nausea/upset stomach           21.3 %     fatigue/asthenia/                  54.5 %   
          lack of strenght  
stomach/abdominal pain       18.1 %     stomach/abdominal pain           51.5 % 
muscle/pain/cramps/           17.4 %     diarrhea                   51.5 % 
weakness  
          dizziness                   51.5 % 
  
 A Pearsons Product Moment Correlation test was run using the number of pages 
and the number of side effects listed in the ads as variables. The significance level was 
.93, not significant at the .05 alpha level, indicating ad size did not correlate to the 
number of side effects listed. 
Anecdotal evidence illustrates this. An ad for Xenical that was five pages listed 
only four side effects, while an ad for Effexor XR that was three pages, listed 11 side 
effects.  The finding that there was no correlation between ad size and number of side 
effects is interesting in that it appears the space available to an advertiser is not one of the 
criteria used to assess how many side effects will be listed.  
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As mentioned in the literature review, there is no legal requirement regarding 
disclosure of side effects. It appears that ads in magazines may fall short of suggestions 
made by the FDA pertaining to DTC. 
As discussed previously in the literature review, the FDA issued the Guidance 
for Industry in 1997.  The Guidance reiterated the FDA requirement that prescription 
drug ads must be non-deceptive.  It also added two more requirements, 1) that a major 
statement must be used to give all of the products most important information in an easy 
to understand language, and 2) the ad must give all information relevant to the products 
indication, including limitations to use in an easy to understand language (Palumbo & 
Mullins, 2002).   
It appears the drug ads are following the Guidances requirement of using a 
major statement but this study suggests that drug ads are not adhering to the 
requirement of conveying all of the products most important risk information.  This is 
illustrated by the fact that some ads do not contain side effects with incidence levels of 
over 30%.  It is also evident in the fact that three of the drug websites did not contain side 
effect percentages in their warnings.   
Even though most of the websites did contain percentages, it must be kept in 
mind, as a limitation to this study, that website information is provided by the drug 
company and in many cases is not precise.  The website is still a public relations vehicle 
for the prescription drug distributors.  Another limitation to this study concerns the fact 
that the advertising agencies hired to promote these prescription drugs for pharmaceutical 
companies were not consulted regarding their advertising practices.  An attempt to find 
out which ad agencies are being utilized by pharmaceutical companies was unsuccessful.  
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A future study concerning DTC could contact pharmaceutical company public relations 
departments or find out which advertising agencies are being used.  Trade literature could 
also be analyzed to better understand the practices used in DTC promotion. 
It is however, interesting to note that less than 10 pharmaceutical manufacturers 
are doing most of the advertising.  Eight companies produced more than 66.7% (22) of 
the 33 drugs advertised.  Pfizer, produced five of the drugs studied, Merck produced four, 
Sanofi-Synthelabo or Bristol-Meyers Squibb produced three, and AstraZeneca, Dermik, 
Aventis, GlaxoSmithKline, and Wyeth each produced two of the 33 drugs studied.  A 
future study could look at corporate culture and decision-making in regard to DTC 
advertising.  Another study could also examine the effect of DTC on doctors and whether 
or not DTC prescription drug advertising is putting undo pressure on physicians to 
prescribe certain medications.             
Also mentioned in the literature review, the United States and New Zealand are 
the only two countries in which DTC advertising is allowed.  It is also pointed out that 
the EU, Canada, and New Zealand all have government provided public health.  With the 
recent legislative action, regarding Medicare and prescription discount cards, and the 
graying of the baby boomer generation in America, it is surprising that the FDA has not 
decided to reevaluate its regulations regarding DTC advertising.     
This study also supports a previous study, mentioned in the literature review, in 
which it was concluded that many people mistakenly believe DTC advertisements go 
through preliminary review by government regulators and that only completely safe 
and extremely effective drugs can be advertised (Bell, Kravitz, & Wilkes, 1999).  This 
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study further supports the idea that people are being misled by these ads and are unable to 
make well-informed decisions based on the information they receive from DTC ads.   
It is also of interest that some websites (Viagra, Synvisc, Noritate) had no side 
effect percentages listed whatsoever. Coupled with the fact that the magazine 
advertisements for these products did not list the side effect percentages, the consumer is 
left with no readily accessible information about the drugs clinical information. 
One unexpected finding was in regard to celebrity endorses who turned out to be 
all athletes. In one case, celebrity endorser Dorothy Hamill was pictured in ads for Vioxx 
that had no side effect warnings. While this does not reflect directly on the research 
questions of this study, it suggests an area for future research.  For example, a study 
regarding consumers perceptions of athletes as the picture of health and whether or not 
seeing an athlete promote a certain drug would make an average person more inclined to 
inquire about that particular drug. 
Also of some concern is the lack of formal communication research regarding 
misleading advertising and more importantly, DTC promotions of prescription medicines.  
Most of the studies regarding prescription drugs and their promotions have been 
published in medical journals.  It is often overlooked that DTC advertising isnt just a 
medical phenomenon; it is also the largest and fastest growing advertising niche in the 
United States.     
Overall, the findings indicate advertising appears to paint a false picture of 
medications. This false picture is in some cases the result of ambiguity, such as in the 
case of imprecise frequency descriptors that may be misleading. In other cases, important 
information such as side effect warnings or side effect percentages was left out.   
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Also of some concern is the type size used to describe side effects.  Because there 
are no formal rules or enforced regulations governing this conduct, it cannot be 
considered illegal.  There is current precedence in regard to required warnings in the area 
of cigarette promotion on both packaging and print advertising.  Advertisers may want to 
consider whether they wish to police themselves or risk future government regulation.  
  Within DTC advertising, there is a great potential to mislead. Possible 
suggestions for correcting the situation could include mandatory guidelines for side effect 
warnings including number of side effects, inclusion of percentages, font size and 
placement. 
This research is exploratory. Further research is necessary to determine if 
consumers are misled by DTC prescription drug ads. This could take the form of 
experiments and surveys in which populations of various age groups are asked to 
evaluate ads. Experimental research could also compare remedial ads with larger sized 
warnings to current ads for evaluation of possible industry guidelines. Evaluation of 
television and print ads in a comparative study would also help provide a foundation of 
research. 
Other future research could possibly address precision ratings across certain 
pharmaceutical companies or drugs.  The studies could find out whether or not certain 
pharmaceutical distributors and advertisers are doing a better or more complete job of 
portraying risk information.  Other suggestions include research on similar drugs for the 
same ailments.  If there are various medications for the same ailments, does this greater 
competition mean that ads are becoming more imprecise in their warnings in order to sell 
their product or make it appear more desirable.   
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  CODING SHEET A 
1.    ID #_________ 
2.    Coder:__________ 
3.    Magazine Name:  (1) AARP the Magazine   (2) Catholic Digest   (3) Yankee       
      (4) Saturday Evening Post   (5) Prevention      
4.    Magazine Date:_____________ 
5.    Page #_______ 
6.    Ad Size: width_______          height_______                other_________ 
      (measured in picas; if more than 1 page, write page size in other blank) 
7.    Type Size of Title:____________ 
   (measured in points) 
8.    Does Ad contain side effect warning?     (1) yes       (2) no  
             (if no skip to #14) 
9.    How Many Side Effects are Listed? _______        
   10.  Does Ad Contain Imprecise Frequency Descriptors?  (1) yes      (2) no   
                                                                                                                 (if no skip to #13) 
11.  Imprecise Frequency Descriptors (IFDs): (mark all that apply)   
  (1) in rare cases   (2) may include   (3) may cause (4) may occur            
      (5) may increase    (6) most common    (7) could cause (8) low incidence     
  (9) low occurrence    (10) some people may experience    (11) usually mild  
      (12) less commonly     (13) most frequently   (14) other (fill in)________________ 
12.  Write all Side Effects Listed and Their Corresponding IFD (Number) from # 12  
if applicable: 
___  ____________________________       ___  __________________________      
___  ____________________________       ___  __________________________ 
___  ____________________________       ___  __________________________          
___  ____________________________       ___  __________________________ 
 45
13. Product:_____________________ 
 (name of prescription drug) 
14.  Product Category: (1) pain relief  (2) depression/mood  (3) health aid   
   (4)asthma/allergy       (5) other (fill in) ________________ 
15.  Does Ad Contain Call to Action?  (1) yes      (2) no 
      (if no, skip to # 17) 
16.  Call to Action: (1) contact physician    (3) link to website  
                      (2) contact pharmacist    (4) toll free number 
17.  Size of Warning:  width_______ height______    
       (measured in picas) 
18.  Type Size of Warning: _________    
    (measured in points)  
19.  Ad is Foldout:   (1) yes (2) no  
20.  Ad has a Multi-Page Layout:  (1) yes     (2) no 
21.  Inside Back Cover:    (1) yes (2) no 
22.  Inside Front Cover:   (1) yes     (2) no 
23.  Back Page Cover:      (1) yes  (2) no   
24.  Ad Contains Color:    (1) yes     (2) no 
25.  Warning is in Color:   (1) yes    (2) no    
26.  Ad contains detailed description of drug:    (1) yes    (2) no 
        (if no, skip to #28) 
27.  Type size of detailed description:__________ 
                                       (measured in points) 
28.  Ad contains celebrity endorser:  (1) yes   (2) no   
                            (if no, skip #29) 
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CODING SHEET B 
    
   1.  Product: _________________ 
  (name of prescription) 
   2.  Http:// Address: ____________________ 
   3.  How Many Side Effects are Listed? ______ 
   4.  Are Percentages of Occurrences Listed with Side Effects? (1) yes    (2) no 
                         (if no, skip #5) 
   5.   Write all Side Effects Listed and Their Percentages of Occurence: 
 ________________________   _______        __________________________   _______ 
 ________________________   _______        __________________________   _______ 
            ________________________   _______        __________________________   _______ 
 ________________________   _______        __________________________   _______ 
 ________________________   _______        __________________________   _______ 
            ________________________   _______        __________________________   _______ 
 ____________________ ______   ______________________ ______ 
 ____________________ ______ ______________________ ______ 
 ____________________ ______ ______________________ ______ 
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Source: Kaiser Family Foundation and Sonderegger Research Center.  (November, 2001).    
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